Semnur Pharmaceuticals, Inc. (SMNR)

OTCMKTS · Delayed Price · Currency is USD

15.00

-8.00 (-34.78%)

At close: Dec 31, 2025

26.26% (1Y)

Market Cap	3.45B
Revenue (ttm)	n/a
Net Income (ttm)	-155.03M
Shares Out	229.74M
EPS (ttm)	-0.97
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	475
Average Volume	484
Open	15.00
Previous Close	23.00
Day's Range	10.00 - 15.00
52-Week Range	9.00 - 23.00
Beta	0.29
RSI	48.84
Earnings Date	Dec 26, 2025

About Semnur Pharmaceuticals

Semnur Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its lead product candidate is SP-102, an opioid novel injectable corticosteroid gel formulation for patients with moderate to severe LRP. The company was founded in 2013 and is headquartered in Palo Alto, California. Semnur Pharmaceuticals, Inc. operates as a subsidiary of Scilex Holding Company. [Read more]

Industry Pharmaceutical Preparations

Founded 2013

Employees 3

Stock Exchange OTCMKTS

Ticker Symbol SMNR

Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.